with peanut allergy in the U.S. and Canada to determine the impact of subcutaneous dupilumab (Dupixent; Sanofi, Regeneron) given every 2 weeks on desensitization to peanut exposure by the 24-week ...

As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the usual forward-looking statements. We would like to remind you that information presented in this call ...

Sanofi SAN-0.15%decrease; red down pointing triangle forecast stronger earnings growth this year and said it planned to launch a $5.2 billion share buyback. The French pharmaceutical company said ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sanofi has tapped Alloy Therapeutics to enable development of a central nervous system drug, agreeing to pay $27.5 million in upfront and near-term fees to access an antisense platform. Alloy is ...

Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone for Sanofi.

Sanofi’s Q3 revenue grew by 12.3% to €13.438 billion, driven by products like Dupixent and influenza vaccines. Dupixent remains a top growth driver, with potential peak sales exceeding $20 ...

Welcome to the Sanofi Presentation at the 43rd J.P. Morgan ... is pretty interesting from our perspective and orthogonal to dupilumab. But also, subsequently we've worked out exactly why former ...

LB-102 is a modified version of amisulpride, a dopamine inhibitor that was developed in the 1980s and marketed by Sanofi as a schizophrenia drug—Solian—outside the U.S. High doses of ...

Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight. The FDA has ...

The TL1A drug would serve as a companion to Sanofi and partner Regeneron's multibillion-dollar blockbuster Dupixent (dupilumab), which is approved across several indications, including atopic ...

The FDA cites contamination at Massachusetts plant where Sanofi makes ingredients used to produce various medicines. HealthDay News — The U.S. Food and Drug Administration has warned the ...